Schrum Private Wealth Management LLC Acquires Shares of 6,300 Bristol-Myers Squibb (NYSE:BMY)

Schrum Private Wealth Management LLC purchased a new stake in Bristol-Myers Squibb (NYSE:BMY) in the 3rd quarter, HoldingsChannel.com reports. The fund purchased 6,300 shares of the biopharmaceutical company’s stock, valued at approximately $326,000.

A number of other large investors have also recently bought and sold shares of BMY. Oppenheimer Asset Management Inc. increased its stake in Bristol-Myers Squibb by 5.8% in the third quarter. Oppenheimer Asset Management Inc. now owns 495,233 shares of the biopharmaceutical company’s stock valued at $25,623,000 after purchasing an additional 27,239 shares during the period. Oppenheimer & Co. Inc. grew its holdings in shares of Bristol-Myers Squibb by 15.2% during the third quarter. Oppenheimer & Co. Inc. now owns 234,211 shares of the biopharmaceutical company’s stock worth $12,118,000 after buying an additional 30,872 shares during the last quarter. Pinnacle Financial Partners Inc increased its position in Bristol-Myers Squibb by 299.4% in the 3rd quarter. Pinnacle Financial Partners Inc now owns 363,443 shares of the biopharmaceutical company’s stock valued at $18,805,000 after acquiring an additional 272,439 shares during the period. Haverford Trust Co raised its stake in Bristol-Myers Squibb by 0.6% during the 3rd quarter. Haverford Trust Co now owns 67,229 shares of the biopharmaceutical company’s stock valued at $3,478,000 after acquiring an additional 382 shares during the last quarter. Finally, Aptus Capital Advisors LLC lifted its position in Bristol-Myers Squibb by 25.5% during the 3rd quarter. Aptus Capital Advisors LLC now owns 21,738 shares of the biopharmaceutical company’s stock worth $1,125,000 after acquiring an additional 4,421 shares during the period. Institutional investors and hedge funds own 76.41% of the company’s stock.

Insiders Place Their Bets

In other news, SVP Phil M. Holzer sold 700 shares of the business’s stock in a transaction on Monday, November 4th. The shares were sold at an average price of $55.62, for a total transaction of $38,934.00. Following the transaction, the senior vice president now directly owns 11,760 shares of the company’s stock, valued at approximately $654,091.20. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, SVP Phil M. Holzer sold 700 shares of the stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $55.62, for a total value of $38,934.00. Following the completion of the transaction, the senior vice president now owns 11,760 shares of the company’s stock, valued at approximately $654,091.20. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Samit Hirawat acquired 1,830 shares of the company’s stock in a transaction on Friday, November 1st. The shares were acquired at an average price of $54.67 per share, for a total transaction of $100,046.10. Following the completion of the acquisition, the executive vice president now directly owns 62,109 shares in the company, valued at $3,395,499.03. The trade was a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.09% of the stock is owned by company insiders.

Bristol-Myers Squibb Price Performance

BMY opened at $58.43 on Thursday. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $61.08. The company has a debt-to-equity ratio of 2.83, a quick ratio of 1.09 and a current ratio of 1.24. The company’s 50 day simple moving average is $52.24 and its 200 day simple moving average is $46.99. The stock has a market capitalization of $118.51 billion, a PE ratio of -16.28, a P/E/G ratio of 21.34 and a beta of 0.44.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.80 EPS for the quarter, topping analysts’ consensus estimates of $1.49 by $0.31. Bristol-Myers Squibb had a positive return on equity of 11.94% and a negative net margin of 15.30%. The company had revenue of $11.89 billion for the quarter, compared to the consensus estimate of $11.26 billion. The company’s quarterly revenue was up 8.4% compared to the same quarter last year. During the same period last year, the business posted $2.00 EPS. As a group, sell-side analysts expect that Bristol-Myers Squibb will post 0.92 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, November 1st. Investors of record on Friday, October 4th were issued a dividend of $0.60 per share. The ex-dividend date of this dividend was Friday, October 4th. This represents a $2.40 annualized dividend and a dividend yield of 4.11%. Bristol-Myers Squibb’s payout ratio is currently -66.85%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on BMY shares. StockNews.com upgraded shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 29th. Sanford C. Bernstein started coverage on shares of Bristol-Myers Squibb in a report on Thursday, October 17th. They set a “market perform” rating and a $56.00 price objective on the stock. Citigroup upped their target price on shares of Bristol-Myers Squibb from $55.00 to $60.00 and gave the stock a “neutral” rating in a research report on Tuesday. Deutsche Bank Aktiengesellschaft decreased their price target on Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating on the stock in a research note on Tuesday, July 23rd. Finally, Leerink Partnrs raised Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a research note on Tuesday. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, two have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $54.07.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.